Drug Search Results
More Filters [+]

Gancotamab

Alternative Names: gancotamab, mm-302, mm302, mm 302
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

MM-302 (Gancotamab) is a liposome containing doxorubicin and conjugated to a monoclonal antibody against the ERBB2 (HER2) receptor, which improves efficacy while reducing toxicityÊ (Sourced from: https://ckb.jax.org/drug/show/7251)

Mechanisms of Action: ERBB2 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merrimack
Company Location: CAMBRIDGE MA 02142
Company CEO: Gary L. Crocker
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gancotamab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Breast Cancer

Phase 1: Brain Cancer|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02735798

P1

Withdrawn

Brain Cancer

2017-06-01

2014-003159-73

P2

Terminated

Breast Cancer

2016-12-31

HERMIONE

P3

Terminated

Breast Cancer

2016-12-01

MM-302-02-01-01

P1

Unknown status

Breast Cancer

2016-08-01

Recent News Events